-
NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men
RESPOND is the largest coordinated study on biological and non-biological factors associated with aggressive prostate cancer in African-American men. The study is an effort to learn why these men disproportionally experience aggressive disease.
-
NCI and VA collaborate to boost veterans’ access to cancer clinical trials
NCI and the Department of Veterans Affairs (VA) are launching the NAVIGATE program at 12 VA facilities across the country to make it easier for veterans to participate in NCI-sponsored clinical trials.
-
NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies
The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.
-
New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments
A novel approach to immunotherapy developed by NCI researchers has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. The findings were published in Nature Medicine.
-
TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy
Findings from the TAILORx clinical trial show chemotherapy does not benefit most women with early breast cancer. The new data, released at the 2018 ASCO annual meeting, will help inform treatment decisions for many women with early-stage breast cancer.